Bio-Techne Corporation

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 572 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Newest filing identified by date: Bio-Techne's fiscal year ends 30 June. The Q3 FY2026 10-Q (period ended 31 Mar 2026, filed 6 May 2026) is the newest filing on EDGAR as of this research (20 Aug 2026); the FY2026 10-K had not yet been filed (Bio-Techne's 10-K has historically filed around 22-24 August, one to four days after this research date). The FY2025 10-K (period ended 30 Jun 2025, filed 22 Aug 2025) was used only for Exhibit 21 and for the prior-period Wilson Wolf carrying value comparison.
• Stock split: Bio-Techne executed a 4-for-1 stock split effected as a stock dividend on 29 Nov 2022 (confirmed in the FY2025 10-K, Note 1: 'All share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the stock split'). Every filing used in this research (all Q2 2026 13F-HRs, the 2025 DEF 14A, the FY2025 10-K, the Q3 FY2026 10-Q) postdates the split and is already reported on the post-split basis, so no restatement was needed for any figure in this file.
• The Wilson Wolf minority stake was researched as an UNVERIFIED LEAD from general knowledge and then CONFIRMED directly from Bio-Techne's own Q3 FY2026 10-Q and cross-checked against the FY2025 10-K: Bio-Techne holds a 19.9% equity-method interest in Wilson Wolf Corporation (private, cell culture devices), acquired for $232 million on 31 Mar 2023 under a forward contract that obligates Bio-Techne to acquire the remaining 80.1% on 31 Dec 2027 (or sooner on a revenue/EBITDA milestone). The percentage (19.9%) is stated explicitly in the filing, so it is sized as a percentage per the project's rule; the dollar figure recorded is the equity-method carrying value ($231,028,000 as of 31 Mar 2026), not a fair-market valuation and not a share count (none is disclosed for the private target).
• Spear Bio is a second, smaller private minority stake (cost-method, $15 million, less than 20% ownership per the filing's own qualitative language, no exact percentage disclosed) and is reported unsized (pct_of_target: null) rather than assumed at 19.9% or any other specific figure.
• Exhibit 21 (subsidiaries list) of the FY2025 10-K was checked and is a bare name list of wholly owned subsidiaries with no ownership-percentage column and no Wilson Wolf or Spear Bio entries (correct, since neither is consolidated); this is a genuine negative, not evidence of an incomplete search.
• Searched the Q3 FY2026 10-Q and the FY2025 10-K in full for: 'equity method', 'non-marketable equity' (not found, filer does not use this exact term; uses 'equity method investment' and 'cost-method' instead), 'joint venture' (only generic risk-factor boilerplate about future M&A activity, no actual disclosed JV beyond Wilson Wolf), 'variable interest entity' (not found), and 'unrealized gain' (present only for derivative/hedging instruments, unrelated to equity holdings). No holdings beyond Wilson Wolf and Spear Bio were found.
• Register self-gate, computed on this final file per the project's chart arithmetic (raw shares summed; no row has rolls_up_into so nothing is reduced): 12 rows summing to 77,425,901 shares (the Officers and directors as a group row, an insider row with nothing rolling into it, counts at full value), against shares_outstanding of 156,568,751, giving 49.45%. This is within the acceptable band (below the 55% ceiling that requires extra corroboration) but toward the high end, so it was corroborated two ways: first, every curated row corresponds to a distinct filer family also present at a comparable size in this project's own 31 Mar 2026 register snapshot (data/registers/TECH.json), with no row invented or duplicated; second, that snapshot's own total_shares_reported (177,392,487 across 572 filers) already exceeds Bio-Techne's shares_outstanding (156,568,751) by about 13%, which is the expected pattern of routine 13F double-counting (sub-advisers and custodians both reporting the same shares) for a stock that is close to fully institutionally held, so a top-12 register at 49% is unsurprising rather than anomalous.
• Wellington Management Group LLP (CIK 0000902219), which appeared at 5,120,185 shares in the 31 Mar 2026 register snapshot (would have ranked among the top 6 holders), was checked directly against its own Q2 2026 13F-HR and found to hold only 10,305 shares as of 30 Jun 2026, a real and large reduction confirmed in the fresh filing (not a data error: 2 lines, both readable, implied price consistent with every other holder). Per the project's rule to prefer the fresh 13F, Wellington is excluded from the top-12 register rather than shown at its stale, much larger snapshot figure; this is recorded here rather than left as a silent gap.
• Maverick Capital Ltd was similarly down sharply from the snapshot (4,739,721 to 1,535,610 shares), also confirmed directly in the fresh Q2 2026 13F-HR and included at its current, smaller size.